The utility of administrative data for surveillance of comorbidity in multiple sclerosis: A validation study

Neuroepidemiology

Volumn 40, Issue 2, 2013, Pages 85-92

  Marrie, Ruth Ann ^a,i   Yu, Bo Nancy ^a   Leung, Stella ^a   Elliott, Lawrence ^a   Caetano, Patricia ^a   Warren, Sharon ^b   Wolfson, Christina ^e,f   Patten, Scott B ^f   Svenson, Lawrence W ^c,d,f   Tremlett, Helen ^g   Fisk, John ^h   Blanchard, James F ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b University Faculty of Medicine   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Administrative data; Comorbidity inflammatory bowel disease; Epilepsy; Irritable bowel syndrome; Lung disease; Migraine; Multiple sclerosis; Prevalence; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DISEASE SURVEILLANCE; ENTERITIS; EPILEPSY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIGRAINE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PREVALENCE; VALIDATION STUDY; ADMINISTRATIVE DATABASE; AGE; DATA BASE; INFLAMMATORY BOWEL DISEASE; MEDICAL RECORD;

ADULT; AGE OF ONSET; AGED; CHRONIC DISEASE; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LUNG DISEASES; MALE; MANITOBA; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; MIGRAINE DISORDERS; MULTIPLE SCLEROSIS; POPULATION SURVEILLANCE; PREVALENCE;

EID: 84867688547     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000343188     Document Type: Article

References (37)

1. Marrie RA, Horwitz RI: Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 2010; 9: 820-828.
2. Chobanian AV, Bakris GL, Black HR, Cush-man WC, Green LA, Izzo JL, Jones DW, Ma-terson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
3. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA: Validation of a self-report co-morbidity questionnaire for multiple sclerosis. Neuroepidemiology 2010; 35: 83-90.
4. Lix L, Yogendran M, Shaw S, Targownick L, Jones J, Bataineh O: Comparing administrative and survey data for ascertaining cases of irritable bowel syndrome: a population-based investigation. BMC Health Serv Res 2010; 10:31.
5. Marrie RA, Yu B, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten S, Svenson L, Tremlett H, Fisk J, Blanchard J, for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis: Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hy-perlipidemia. Mult Scler 2012; 18: 1310-1319.
6. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ: Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler 2007; 13: 1038-1045.
7. Koch M, Uyttenboogaart M, Polman S, De Keyser J: Seizures in multiple sclerosis. Epi-lepsia 2008; 49:948-953.
8. Langer-Gould A, Albers K, Van Den Eeden S, Nelson L: Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010; 16: 855-861.
9. Health Information Management Branch: Population Report. Winnipeg, Manitoba, Manitoba Health and Healthy Living, 2008.
10. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L: The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010; 74:465-471.
11. Marrie RA, Yu B, Leung S, Elliott L, Warren S, Wolfson C, Tremlett H, Fisk J, Blanchard J: The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiol-ogy 2012; 39:135-142.
12. Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF: The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006; 101:1559-1568.
13. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
14. Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
15. Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM: Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepide-miol Drug Saf 2006; 15:47-56.
16. Goff SL, Feld A, Andrade SE, Mahoney L, Beaton SJ, Boudreau DM, Davis RL, Goodman M, Hartsfield CL, Platt R, Roblin D, Smith D, Yood MU, Dodd K, Gurwitz JH: Administrative data used to identify patients with irritable bowel syndrome. J Clin Epidemiol 2008; 61: 617-621.
17. Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM: Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004; 99: 486-491.
18. Borgaonkar M, Irvine E: Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444-454.
19. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Comorbidity, so-cioeconomic status, and multiple sclerosis. Mult Scler 2008; 14:1091-1098.
20. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G: Immune activation in patients with irritable bowel syndrome. Gastroenterolog y 2007; 132: 913-920.
21. Fukudo S, Kanazawa M: Gene, environment, and brain-gut interactions in irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26: 110-115.
22. Hungin APS, Chang L, Locke GR, Dennis EH, Barghout V: Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-1375.
23. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH, The New York State Multiple Sclerosis Consortium: A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5:369-376.
24. Henderson RD, Bain CJ, Pender MP: The occurrence of autoimmune d iseases in patients with multiple sclerosis and their families. J Clin Neurosci 2000; 7: 434-437.
25. Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, Sadovnick AD, Ebers GC: The occurrence of autoimmune disease in Canadian families with multiple sclerosis. Lancet Neurol 2007; 6: 604-610.
26. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS: Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992; 135:1029-1041.
27. Kang J-H, Chen Y-H, Lin H-C: Comorbidi-ties amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 2010; 17:1215-1219.
28. Egesten A, Brandt L, Olsson T, Granath F, Inghammar M, Löfdahl C-G, Ekbom A: Increased prevalence of multiple sclerosis among COPD patients and their first-degree relatives: a population-based study. Lung 2008; 186: 173-178.
29. Cruz AA, Mantzouranis E, Matricardi PM, Minelli E, Aït-Khaled N, Bateman ED, Baena-Cagnani C, Boland M, Buist SA, Canonica GW, Carlsen K-H, Dahl R, Fabbri LM, Fukuchi Y, Grouse L, Humbert M, Lenfant C, Malo JL, McNicholas WT, Pawankar R, Rabe KF, Simons FER, Turnbull A, Valovirta E, Cauwenberge Pv, Viegi G, Weel CV, Wenzel S, Zhong N: Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach; in Bousquet J, Khaltaev N (eds). Geneva, WHO, 2007, pp 5-31.
30. Putzki N, Pfriem A, Limmroth V, Yaldizli Ö, Tettenborn B, Diener HC, Katsarava Z: Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol 2009; 16: 262-267.
31. Kister I, Caminero A, Monteith T, Soliman A, Bacon T, Bacon J, Kalina J, Inglese M, Herbert J, Lipton R: Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J Headache Pain 2010; 11:417-425.
32. Patti F, Nicoletti A, Pappalardo A, Castiglio-ne A, Lo Fermo S, Messina S, DAmico E, Cimino V, Zappia M: Frequency and severity of headache is worsened by interferon-13 therapy in patients with multiple sclerosis. Acta Neurol Scand 2012; 125:91-95.
33. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L: Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 2010; 35: 267-274.
34. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T: The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and under-treated. Mult Scler 2009; 15:385-392.
35. Mo F, Choi BCK, Li FCK, Merrick J: Using Health Utility Index (HUI) for measuring the impact on health-related quality of life (HRQL) among individuals with chronic diseases. ScientificWorldJournal 2004; 4: 746-757.
36. Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM: Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chron Obstruct Pulmon Dis 2008; 3: 693-699.
37. Huzel L, Roos LL, Anthonisen NR, Manfre-da J: Diagnosing asthma: the fit between survey and administrative database. Can Respir J 2002; 9: 407-412.